These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 20004471)

  • 21. Imatinib for hepatocellular cancer--focus on pharmacokinetic/pharmacodynamic modelling and liver function.
    Treiber G; Wex T; Schleyer E; Troeger U; Hosius C; Malfertheiner P
    Cancer Lett; 2008 Feb; 260(1-2):146-54. PubMed ID: 18083304
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Experimental design in reversed-phase high-performance liquid chromatographic analysis of imatinib mesylate and its impurity.
    Medenica M; Jancic B; Ivanovic D; Malenovic A
    J Chromatogr A; 2004 Mar; 1031(1-2):243-8. PubMed ID: 15058589
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HPLC-MS method for the simultaneous quantification of the antileukemia drugs imatinib, dasatinib and nilotinib in human peripheral blood mononuclear cell (PBMC).
    D'Avolio A; Simiele M; De Francia S; Ariaudo A; Baietto L; Cusato J; Fava C; Saglio G; Di Carlo F; Di Perri G
    J Pharm Biomed Anal; 2012 Feb; 59():109-16. PubMed ID: 22036594
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Imatinib assay by HPLC with photodiode-array UV detection in plasma from patients with chronic myeloid leukemia: Comparison with LC-MS/MS.
    Roth O; Spreux-Varoquaux O; Bouchet S; Rousselot P; Castaigne S; Rigaudeau S; Raggueneau V; Therond P; Devillier P; Molimard M; Maneglier B
    Clin Chim Acta; 2010 Feb; 411(3-4):140-6. PubMed ID: 19853594
    [TBL] [Abstract][Full Text] [Related]  

  • 25. High-performance liquid chromatography with solid-phase extraction for the quantitative determination of nilotinib in human plasma.
    Miura M; Takahashi N; Sawada K
    Biomed Chromatogr; 2010 Jul; 24(7):789-93. PubMed ID: 19904720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A new HPLC-UV validated method for therapeutic drug monitoring of tyrosine kinase inhibitors in leukemic patients.
    Pirro E; De Francia S; De Martino F; Fava C; Ulisciani S; Cambrin GR; Racca S; Saglio G; Di Carlo F
    J Chromatogr Sci; 2011; 49(10):753-7. PubMed ID: 22080802
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantification of imatinib in human serum: validation of a high-performance liquid chromatography-mass spectrometry method for therapeutic drug monitoring and pharmacokinetic assays.
    Rezende VM; Rivellis A; Novaes MM; de Alencar Fisher Chamone D; Bendit I
    Drug Des Devel Ther; 2013; 7():699-710. PubMed ID: 23946646
    [TBL] [Abstract][Full Text] [Related]  

  • 28. High-performance liquid chromatographic-ultraviolet assay for the simultaneous quantitation of BMS-181101 and its putative hydroxy metabolites in rat and monkey plasma.
    Shah VR; Srinivas NR; Campbell DA; Mantha S; Duncan G; Schuster A; Whigan DW; Shyu WC
    Biomed Chromatogr; 1996; 10(3):135-8. PubMed ID: 8792865
    [TBL] [Abstract][Full Text] [Related]  

  • 29. High-performance liquid chromatography method with ultraviolet detection for the quantification of the BCR-ABL inhibitor nilotinib (AMN107) in plasma, urine, culture medium and cell preparations.
    Pursche S; Ottmann OG; Ehninger G; Schleyer E
    J Chromatogr B Analyt Technol Biomed Life Sci; 2007 Jun; 852(1-2):208-16. PubMed ID: 17291840
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bioequivalence study of 400 and 100 mg imatinib film-coated tablets in healthy volunteers.
    Ostrowicz A; Mikołajczak PL; Wierzbicka M; Boguradzki P
    Acta Pol Pharm; 2014; 71(5):843-54. PubMed ID: 25362813
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Simultaneous Determination of Imatinib, Dasatinib, and Nilotinib by Liquid Chromatography-Tandem Mass Spectrometry and Its Application to Therapeutic Drug Monitoring.
    Wojnicz A; Colom-Fernández B; Steegmann JL; Muñoz-Calleja C; Abad-Santos F; Ruiz-Nuño A
    Ther Drug Monit; 2017 Jun; 39(3):252-262. PubMed ID: 28490048
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Quantification of the anti-leukemia drug STI571 (Gleevec) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry.
    Bakhtiar R; Khemani L; Hayes M; Bedman T; Tse F
    J Pharm Biomed Anal; 2002 Jun; 28(6):1183-94. PubMed ID: 12049982
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometry.
    Haouala A; Zanolari B; Rochat B; Montemurro M; Zaman K; Duchosal MA; Ris HB; Leyvraz S; Widmer N; Decosterd LA
    J Chromatogr B Analyt Technol Biomed Life Sci; 2009 Jul; 877(22):1982-96. PubMed ID: 19505856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A validated LC method for imatinib mesylate.
    Vivekanand VV; Sreenivas Rao D; Vaidyanathan G; Sekhar NM; Avijit Kelkar S; Ramachandra Puranik P
    J Pharm Biomed Anal; 2003 Dec; 33(5):879-89. PubMed ID: 14656579
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Population pharmacokinetics of imatinib in Iranian patients with chronic-phase chronic myeloid leukemia.
    Golabchifar AA; Rezaee S; Ghavamzadeh A; Alimoghaddam K; Dinan NM; Rouini MR
    Cancer Chemother Pharmacol; 2014 Jul; 74(1):85-93. PubMed ID: 24817601
    [TBL] [Abstract][Full Text] [Related]  

  • 36. High-performance Liquid Chromatographic Ultraviolet Detection of Nilotinib in Human Plasma from Patients with Chronic Myelogenous Leukemia, and Comparison with Liquid Chromatography-Tandem Mass Spectrometry.
    Nakahara R; Satho Y; Itoh H
    J Clin Lab Anal; 2016 Nov; 30(6):1028-1030. PubMed ID: 27194024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ultrafast Online SPE-MS/MS Method for Quantification of 3 Tyrosine Kinase Inhibitors in Human Plasma.
    Vrobel I; Janečková H; Faber E; Bouchalová K; Mičová K; Friedecký D; Adam T
    Ther Drug Monit; 2016 Aug; 38(4):516-24. PubMed ID: 27414975
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry.
    Bakhtiar R; Lohne J; Ramos L; Khemani L; Hayes M; Tse F
    J Chromatogr B Analyt Technol Biomed Life Sci; 2002 Mar; 768(2):325-40. PubMed ID: 11888061
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Monitoring of imatinib targeted delivery in human leukocytes.
    Kralj E; Žakelj S; Trontelj J; Pajič T; Preložnik Zupan I; Černelč P; Ostanek B; Marc J; Kristl A
    Eur J Pharm Sci; 2013 Sep; 50(1):123-9. PubMed ID: 23643738
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Metabolism and disposition of imatinib mesylate in healthy volunteers.
    Gschwind HP; Pfaar U; Waldmeier F; Zollinger M; Sayer C; Zbinden P; Hayes M; Pokorny R; Seiberling M; Ben-Am M; Peng B; Gross G
    Drug Metab Dispos; 2005 Oct; 33(10):1503-12. PubMed ID: 16006570
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.